Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
FDA grants approval for new formulation of TriCor
December 7th, 2004
Abbott (ABT) announced that it received U.S. Food and Drug Administration approval to market a new formulation of TriCor (fenofibrate) Tablets for the treatment of lipid disorders such as mixed dyslipidemia - conditions related to abnormal levels of fats, including cholesterol and triglycerides, in the bloodstream. The new formulation of TriCor was developed using a new nanoparticle technology so it can be taken with or without food. Until now, TriCor had to be taken with food to enable optimal absorption of TriCor in the body. Taking the previous version of TriCor with food compared to without food could result in an approximate 35% difference in...
Source: Cardiovascular Business Week (2004-12-07)
|
